AzTrials
AzTrials

Lung CancerNEBULANCT04553809

Navigation Endobronchial Ultrasound

A study testing ENB and ENB in combination with rEBUS in people with Lung Cancer, run by Amanda Dandanell Juul at 1 site in Denmark.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Lung cancer is the primary cause of cancer related deaths in Denmark. In order to improve the prognosis diagnosis in earlier stages are needed. This will however require improved sampling techniques from very small lung lesions. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Lung Cancer
What is being tested?
ENB and ENB in combination with rEBUS
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
200 participants
Where
1 siteDenmark
Study dates
12 Oct 2020to 1 Mar 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Examination for lung cancer
  • Peripheral lung lesion or lung nodule surrounded by normal lung parenchyma
  • Written and orally informed consent

Who cannot join

  • Patient has medical devices in which ENB is contraindicated (e.g. implanted pacemaker or defibrillator)
  • Pregnancy

Trial locations and contacts

1 site in 1 country.

Denmark1 site
  • Departement of respiratory medicin

    Odense, Region Syddanmark, 5000

Other trials in Denmark

About this study

Official title: The Efficacy of Combining Endoscopic Modalities for the Diagnosis of Solitary Pulmonary Lesions

Lung cancer is the primary cause of cancer related deaths in Denmark. In order to improve the prognosis diagnosis in earlier stages are needed. This will however require improved sampling techniques from very small lung lesions.

One method involves the use of a radial ultrasound probe inserted in the working channel of the bronchoscope, to more accurately identify the lung lesions before sampling them (rEBUS). The other method involves the use of electromagnetic navigation bronchoscopy (ENB) to guide the operator to the lung lesion.

This study aims to determine whether a combination of rEBUS and ENB is superior to ENB alone in biopsy sampling. The study will be conducted as a non-blinded RCT. Furthermore, we will make an estimate of the hospital costs of the entire diagnostic work up for lung cancer when combining ENB and rEBUS compared to ENB alone.

Read the detailed description

Background:

Despite recent years' improvement regarding the treatment of lung cancer, it remains the leading cause of cancer deaths in Denmark. This is partly due to many patients being diagnosed in an advanced stage limiting the possibilities of curative treatment. Much attention has therefore been aimed at developing tools for early identification of patients with possible lung cancer . Screening or easy access to CT of the chest may help to identify patients with possible early stage lung cancer. Performing biopsies of small lung lesions in a safe manner without inexpedient complications, however, is an ongoing diagnostic challenge especially for the increasing elderly patient population and patients with decreased lung function. If patients are to benefit from an improved identification of possible early stage lung cancer, it is necessary to also further improve the methods for obtaining biopsies in this patient population in order to decrease the morbidity during the diagnostic work-up and to prepare the patients for treatment in a secure manner.

Current methods for performing biopsies of small lung lesions are transthoracic, endoscopic or surgical. When compared to surgery, the endoscopic methods have the advantages of being easily accessible, cheap, safe with a very low risk of complications, and have limited patient discomfort following the procedure. The major drawback is the diagnostic yield still being significantly lower than surgery.

In recent years, two methods have been developed which seem to improve the diagnostic yield of bronchoscopy for diagnosing peripheral lung lesions. The rationale behind both techniques is to improve identification of the lung lesions prior to performing the biopsies and thereby improving the chance of obtaining representative tissue samples. One method involves the use of a radial ultrasound probe inserted in the working channel of the bronchoscope, which enables the proceduralist to perform radial endobronchial ultrasound (rEBUS) to more accurately identify the lung lesions before sampling them. The other method involves the use of electromagnetic navigation bronchoscopy (ENB) to guide the operator to the lung lesion. One small randomised clinical trial has indicated that the diagnostic yield can be further improved by a multimodal approach, which combines both rEBUS and ENB in the same procedure. The drawbacks of such a combination are however increased costs and procedure time, thus limiting the number of procedures which can be performed within a given time frame.

This PhD thesis aims to determine whether a combination of rEBUS and ENB is superior to ENB alone in patients with suspected lung cancer due to a peripheral lung lesion as well as an estimate of the hospital costs of the entire diagnostic work up for lung cancer when combining ENB and rEBUS as compared to ENB alone.

Hypotheses:

  1. The diagnostic yield of ENB in combination with rEBUS is equal to ENB alone in patients with peripheral lung lesions or solitary lung nodules (null hypothesis)
  2. The hospital costs of the entire diagnostic work up for lung cancer when combining ENB and rEBUS is the same when compared to an approach with ENB alone (null hypothesis)

Research questions:

  1. Is the diagnostic yield of ENB in combination with rEBUS different from ENB alone in diagnosing lung lesions?
  2. What are the hospital costs of the entire diagnostic workup for lung cancer when combining ENB and rEBUS in comparing with ENB alone?

Navigation EndoBronchial ULtrAsound (NEBULA):

Hypotheses The study examines the following null-hypothesis: The diagnostic yield of ENB in combination with rEBUS is not superior to ENB alone in patients with peripheral lung lesions or solitary lung nodules.

Objectives To determine which bronchoscopy approach should be considered standard for examining patients with suspected lung cancer due to a peripheral lung lesion.

Methods Study design Multicentre, randomized, non-blinded clinical trial Pre- and post-procedure Preparations prior and following the bronchoscopy procedure are done in accordance with local guidelines. Procedures will be performed either under conscious sedation using midazolam and fentanyl or in general anesthetic depending on the set up of the center performing the procedures. Other medication given during the procedure is also given accordance with local guidelines.

Reference test Histology or cytology results will be used as the reference test for all malignant as well as non-malignant conditions that could be diagnosed based on these. Clinical follow-up including imaging for at least 6 months with no signs of malignancy and results of additional diagnostic procedures will be used as the reference test in patients in which a final diagnosis cannot be established based on histology or cytology results.

Sample size and statistics In a previous study by Eberhardt et al. the diagnostic yield of ENB and combined rEBUS/ENB was 59 % and 88 %, respectively. The diagnostic yield of the intervention arm in the planned study may be lower due to selection of patients with smaller lesions and multicentre approach rather than a single centre study performed by experts. If the total diagnostic yield is 60 % in the control group (ENB) and 80 % in the intervention group (rEBUS/ENB), then a power of 80 % at the 5 % level is obtained with a sample size of 184 patients. Allowing for a 10 % dropout it is planned to enroll 200 patients in the study. The χ2 test, alternatively the Fischer exact test will be used to establish whether there is a difference in the primary endpoint. All results will be assessed using intention to treat principles.

Ethics:

The studies and analyses will be conducted in accordance with the amended Declaration of Helsinki and Data Protection Agency in Denmark and the Medical Ethics Committee.:

The studies do not interfere with choice of other diagnostic tests performed in the patients (e.g. EBUS / EUS-b for mediastinal staging). The patients are treated and followed up according to national and institutional guidelines. The protocols for studies II and III do not influence treatment or follow-up.

Clinical relevance:

The results will help to clarify how one of the most important diagnostic procedures for patients with suspected lung cancer due to a peripheral lung lesion should be used in clinical practice. The results of the project can be directly implemented at a national scale once the results are available.

Economy:

Project expenses are expected to be partially covered by funds from the Kræftens Bekæmpelse - Centre for Lung Cancer Research with a grant of 1 mill. DKK. Funding of expenses for procedures (e.g. scans and invasive procedures) will be covered as part of the lung cancer diagnostic work up "package" covered by the department.

Participating departments:

Currently the following departments have agreed to participate:

  • Department of Respiratory Medicine, Bispebjerg Hospital
  • Department of Respiratory Medicine, Aalborg University Hospital
  • Department of Respiratory Medicine, Odense University Hospital
Conditions
Lung Cancer
Being tested
ENB, ENB in combination with rEBUS
Keywords
lung cancer diagnotics
Medical subject headings
Lung Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ENBProcedure or surgery

    ENB for biopsy sampling of peripheral lung lesion

  • ENB in combination with rEBUSProcedure or surgery

    The combination of ENB and rEBUS for biopsy sampling of peripheral lung lesions

Study groups in NCT04553809
Study groupRoleWhat they receive
KontrolActive comparatorPatients undergoing examination for lung cancer with the use of electromagnetic navigation bronchoscopy for biopsy sampling
Receives: Procedure: ENB
InterventionExperimentalPatients undergoing examination for lunge cancer with the use of electromagnetic navigation bronchoscopy and radial endobronchial ultrasound for biopsy sampling.
Receives: Procedure: ENB in combination with rEBUS

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Total diagnostic yield

    Total diagnostic yield, being defined as a tissue biopsy allowing a definite diagnosis of either a malignant or benign condition in the lung in proportion to the total number of procedures performed.

    Measured: 6 months

Secondary outcomes (10)
  1. Malignant diagnostic yield

    Diagnostic yield of malignant conditions, being defined as a tissue biopsy allowing a definite diagnosis of a malignant condition in the lung

    Measured: 6 months

  2. Non-malignant diagnostic yield

    Diagnostic yield of non-malignant conditions, being defined as a tissue biopsy allowing a definite diagnosis of a benign condition in the lung

    Measured: 6 months

  3. Complications

    Total proportion of patients with procedure complications

    Measured: 1 week

  4. Severe complications

    Total proportion of patients with severe procedure complications

    Measured: 1 week

  5. Ready to treat

    Time from referral to "ready to treat"

    Measured: 7 months

  6. Discomfort

    Patient reported procedure discomfort during the endoscopic procedure. Reported in a questionnaire efter the procedure.

    Measured: 2 weeks

  7. Patient satisfaction

    Patient reported procedure satisfaction. Reported in a questionnaire after the procedure in a scale from 1 -10.

    Measured: 2 weeks

  8. Procedure time

    Procedure time differens between the two arms

    Measured: 1 week

  9. Procedure costs

    Differens in procedure cost for the two arms, reported in daniske kroner or converted to euro for publications

    Measured: 2 years

  10. Entire work-up costs

    Hospital costs of the entire diagnostic workup incl. admissions and expenses for treating adverse events from referral to end of "cancer package". Reported in danish kroner or converted to euro for publication.

    Measured: 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Sep 2020
  2. Study start12 Oct 2020
  3. Primary completion30 Aug 2024
  4. Study completion1 Mar 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
200 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04553809
Sponsor's protocol ID
ENBPhD
Acronym
NEBULA
Status last verified
May 2025
First submitted
3 Sep 2020
Last updated
14 May 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Eberhardt R, Anantham D, Ernst A, Feller-Kopman D, Herth F. Multimodality bronchoscopic diagnosis of peripheral lung lesions: a randomized controlled trial. Am J Respir Crit Care Med. 2007 Jul 1;176(1):36-41. doi: 10.1164/rccm.200612-1866OC. Epub 2007 Mar 22.

    PubMed 17379850
  • Brownback KR, Quijano F, Latham HE, Simpson SQ. Electromagnetic navigational bronchoscopy in the diagnosis of lung lesions. J Bronchology Interv Pulmonol. 2012 Apr;19(2):91-7. doi: 10.1097/LBR.0b013e31824dd9a1.

    PubMed 23207349
  • Zhang W, Chen S, Dong X, Lei P. Meta-analysis of the diagnostic yield and safety of electromagnetic navigation bronchoscopy for lung nodules. J Thorac Dis. 2015 May;7(5):799-809. doi: 10.3978/j.issn.2072-1439.2015.04.46.

    PubMed 26101635
  • Ali MS, Trick W, Mba BI, Mohananey D, Sethi J, Musani AI. Radial endobronchial ultrasound for the diagnosis of peripheral pulmonary lesions: A systematic review and meta-analysis. Respirology. 2017 Apr;22(3):443-453. doi: 10.1111/resp.12980. Epub 2017 Feb 8.

    PubMed 28177181
  • Khan KA, Nardelli P, Jaeger A, O'Shea C, Cantillon-Murphy P, Kennedy MP. Navigational Bronchoscopy for Early Lung Cancer: A Road to Therapy. Adv Ther. 2016 Apr;33(4):580-96. doi: 10.1007/s12325-016-0319-4. Epub 2016 Mar 22.

    PubMed 27084723
  • Herth FJ, Eberhardt R, Becker HD, Ernst A. Endobronchial ultrasound-guided transbronchial lung biopsy in fluoroscopically invisible solitary pulmonary nodules: a prospective trial. Chest. 2006 Jan;129(1):147-50. doi: 10.1378/chest.129.1.147.

    PubMed 16424425
  • Wang Memoli JS, Nietert PJ, Silvestri GA. Meta-analysis of guided bronchoscopy for the evaluation of the pulmonary nodule. Chest. 2012 Aug;142(2):385-393. doi: 10.1378/chest.11-1764.

    PubMed 21980059
  • Haas AR, Vachani A, Sterman DH. Advances in diagnostic bronchoscopy. Am J Respir Crit Care Med. 2010 Sep 1;182(5):589-97. doi: 10.1164/rccm.201002-0186CI. Epub 2010 Apr 8.

    PubMed 20378726
  • Munoz-Largacha JA, Litle VR, Fernando HC. Navigation bronchoscopy for diagnosis and small nodule location. J Thorac Dis. 2017 Mar;9(Suppl 2):S98-S103. doi: 10.21037/jtd.2017.01.57.

    PubMed 28446971
  • Evison M, Crosbie PA, Morris J, Martin J, Barber PV, Booton R. Can computed tomography characteristics predict outcomes in patients undergoing radial endobronchial ultrasound-guided biopsy of peripheral lung lesions? J Thorac Oncol. 2014 Sep;9(9):1393-7. doi: 10.1097/JTO.0000000000000249.

    PubMed 25122434
  • Schreiber G, McCrory DC. Performance characteristics of different modalities for diagnosis of suspected lung cancer: summary of published evidence. Chest. 2003 Jan;123(1 Suppl):115S-128S. doi: 10.1378/chest.123.1_suppl.115s.

    PubMed 12527571

Questions about this trial

What is this clinical trial studying?

A study testing ENB and ENB in combination with rEBUS in people with Lung Cancer, run by Amanda Dandanell Juul at 1 site in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 14 May 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Total diagnostic yield (time frame: 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04553809, which also lists 11 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 May 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
Navigation Endobronchial Ultrasound (NCT04553809) | AzTrials